Orexo AB
Research Orexo AB (ORX) on Bullrun: market cap SEK 474.92M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerORX
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencySEK
- Market capSEK 474.92M
- Financial periodQ2 2026
- RevenueSEK 3.50M
- Net income-SEK 100.40M
- Free cash flow-SEK 95.00M
- Gross margin97.1%
Valuation Snapshot
latest market cap is SEK 474.92M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 26.00M | SEK 639.30M | n/a | 44.2% | n/a | SEK 912.40M | SEK 491.50M | SEK 490.60M |
| FY2024 | SEK 590.00M | -SEK 203.00M | -SEK 35.70M | 87.8% | -5.89 | SEK 123.30M | SEK 476.00M | -SEK 126.30M |
| FY2023 | SEK 638.80M | -SEK 128.30M | -SEK 113.50M | 86.1% | -3.73 | SEK 171.00M | n/a | SEK 58.90M |
| FY2022 | SEK 624.30M | -SEK 177.60M | -SEK 175.40M | 83.6% | -5.17 | SEK 132.20M | n/a | SEK 193.90M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-06 | SEK 474.92M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Orexo AB
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori. The company is developing Izipry for opioid overdose;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Orexo AB's market cap?
Orexo AB's market capitalization is SEK 474.92M.
What does Orexo AB do?
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori.